Spots Global Cancer Trial Database for Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Official Title: A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Study ID: NCT04309084
Conditions
Interventions
Study Description
Brief Summary: This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Colorado Blood Cancer Institute, Denver, Colorado, United States
Washington University, Saint Louis, Missouri, United States
Roswell Park Comprehensive Cancer Institute, Buffalo, New York, United States
Tennessee Oncology, Nashville, Tennessee, United States
Contact Details
Name: Adrian Kilcoyne, MD
Affiliation: Celularity Incorporated
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
